Open Payments

St Bernards Medical Center

Type
Teaching hospital
Where
JONESBORO, AR
Medicare CCN
040020
Received
$712,056 in 49 records, 2021 ($2,569 general, $709,486 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2021General payment2$2,569
2021Research payment47$709,486

By company

CompanyRecordsAmountYears
Novartis Pharmaceuticals Corporation1$273,7322021
Merck Sharp & Dohme LLC4$222,9212021
Amgen Inc.4$98,9412021
Boston Scientific Corporation15$49,6142021
Eli Lilly and Company5$31,9552021
PFIZER INC.4$14,8552021
SEAGEN INC.4$8,0002021
Endologix LLC1$4,0622021
Celgene Corporation1$3,8602021
Medline Industries LP2$2,5692021
Pharmacyclics LLC, an AbbVie Company7$1,0502021
Incyte Corporation1$4942021

By nature of payment

NatureRecordsAmount
Research payment47$709,486
Compensation for services other than consulting, including serving as faculty or as a speaker at a v2$2,569

Records

DateCompanyAmountNatureFormProductStudyYear
2021-12-31Merck Sharp & Dohme LLC$119,367Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab2021
2021-12-31Merck Sharp & Dohme LLC$71,661Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab ver2021
2021-12-31Merck Sharp & Dohme LLC$21,891Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab ver2021
2021-12-31Merck Sharp & Dohme LLC$10,000Research paymentIn-kind items and services Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab2021
2021-12-16SEAGEN INC.$2,000Research paymentCash or cash equivalentTUKYSA Drug, OncologyStudy of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas2021
2021-12-15Endologix LLC$4,062Research paymentCash or cash equivalentDetour II Study2021
2021-12-14Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYinformCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL)2021
2021-12-06Boston Scientific Corporation$2,063Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductELEGANCE2021
2021-12-06Boston Scientific Corporation$1,338Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductSAVAL PIVOTAL2021
2021-11-23PFIZER INC.$2,119Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2021
2021-11-05PFIZER INC.$331Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2021
2021-11-01Boston Scientific Corporation$7,101Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductELEGANCE2021
2021-11-01Boston Scientific Corporation$1,702Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductSAVAL PIVOTAL2021
2021-10-08PFIZER INC.$2,205Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2021
2021-10-04Boston Scientific Corporation$7,283Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductELEGANCE2021
2021-10-04Boston Scientific Corporation$248Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductSAVAL PIVOTAL2021
2021-09-08Eli Lilly and Company$480Research paymentIn-kind items and servicesEMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE2021
2021-09-07Boston Scientific Corporation$4,408Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductSAVAL PIVOTAL2021
2021-09-07Boston Scientific Corporation$2,317Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductELEGANCE2021
2021-08-03Boston Scientific Corporation$4,014Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductELEGANCE2021
2021-07-26SEAGEN INC.$2,000Research paymentCash or cash equivalentTUKYSA Drug, OncologyStudy of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas2021
2021-07-06Boston Scientific Corporation$876Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductELEGANCE2021
2021-06-07Boston Scientific Corporation$8,259Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductSAVAL PIVOTAL2021
2021-05-18Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYinformCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL)2021
2021-05-18Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYinformCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL)2021
2021-05-04Boston Scientific Corporation$3,817Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductSAVAL PIVOTAL2021
2021-05-01PFIZER INC.$10,200Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A 2021
2021-04-26Eli Lilly and Company$733Research paymentIn-kind items and servicesA STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN2021
2021-04-24Amgen Inc.$11,820Research paymentCash or cash equivalentNplate Biological, HematologyLCM:A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 12021
2021-04-19Medline Industries LP$1,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBiosense Webster EP Mapping Sensor Device, Reprocessing2021
2021-03-28Amgen Inc.$275Research paymentIn-kind items and servicesNeulasta Biological, OncologyProspective Observational Study of Onpro vs SOC.2021
2021-03-25SEAGEN INC.$2,000Research paymentCash or cash equivalentTUKYSA Drug, OncologyStudy of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas2021
2021-03-15Boston Scientific Corporation$1,660Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductSAVAL PIVOTAL2021
2021-02-26Medline Industries LP$1,269Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSt. Jude Medical EP Catheters Device, Reprocessing2021
2021-02-15Boston Scientific Corporation$2,687Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductSAVAL PIVOTAL2021
2021-02-10Celgene Corporation$3,860Research paymentCash or cash equivalentRevlimid Drug, HematologyConnect MDS/AML2021
2021-02-08Amgen Inc.$57,474Research paymentIn-kind items and servicesNplate Biological, HematologyLCM:A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 12021
2021-02-08Amgen Inc.$29,372Research paymentIn-kind items and servicesNplate Biological, HematologyLCM: A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 22021
2021-02-02Eli Lilly and Company$7,029Research paymentCash or cash equivalentA RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD2021
2021-01-26Eli Lilly and Company$23,624Research paymentCash or cash equivalentA STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN2021
2021-01-26Eli Lilly and Company$87Research paymentIn-kind items and servicesA RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD2021
2021-01-25SEAGEN INC.$2,000Research paymentCash or cash equivalentTUKYSA Drug, OncologyStudy of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas2021
2021-01-20Incyte Corporation$494Research paymentCash or cash equivalentPROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED 2021
2021-01-19Novartis Pharmaceuticals Corporation$273,732Research paymentCash or cash equivalentKISQALI Drug, ONCOLOGYRIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE2021
2021-01-19Boston Scientific Corporation$1,835Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductSAVAL PIVOTAL2021
2021-01-14Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYinformCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL)2021
2021-01-14Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYinformCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL)2021
2021-01-14Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYinformCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL)2021
2021-01-14Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYinformCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL)2021

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Craighead CountyJonesboro city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Jonesboro, AR, county Craighead County, AR, state Arkansas; placed by its city name.

MeasurePlace (city or town)
Jonesboro, AR
County
Craighead County, AR
State
Arkansas
Population B0100380,137113,2493,049,391
Population, 2020 census P178,576111,2313,011,524
Median age B0100233.934.538.5
Under 18 B0100124.0%25.2%23.1%
65 and over B0100114.2%13.9%17.6%
Households B1100131,91344,4371,205,987
Foreign born B050024.6%3.7%5.4%
Median household income B19013$55,424$59,548$60,773
Median family income B19113$72,057$75,703$76,968
Per capita income B19301$33,544$33,774$34,225
Poverty rate B1700122.8%20.1%16.0%
Unemployment rate B230256.3%5.6%4.9%
Civilian labor force B2302538,91255,5351,411,269
Mean commute (minutes) B0801318.019.622.5
Bachelor's degree or higher B1500331.8%29.7%25.7%
Housing units B2500135,00248,8851,394,673
Owner-occupied B2500354.3%60.1%66.4%
Renters B2500345.7%39.9%33.6%
Median home value B25077$223,200$210,400$188,000
Median gross rent B25064$956$958$947
White, not Hispanic B0300263.0%70.8%67.4%
Black B0300222.7%16.6%14.6%
Hispanic or Latino B030027.5%6.3%9.0%
Asian B030021.6%1.2%1.6%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 3.9% in Sep 2026 (4.2% a year earlier); per capita personal income $61,697 in 2025, up 31% in five years (+5.2% after inflation); Unemployment rate: 3.9% in Sep 2016 to 3.8% in Oct 2026; low 2.9%, high 10.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Jonesboro, AR.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.